A presentation on the HPTN 084 study delivered on January 27, 2021, confirmed the results announced when the trial was stopped early in November 2020 but added new details.
This presentation focused on women randomly allocated to receive injectable PrEP (every eight weeks) or oral PrEP (every day).
The study used a 'double-dummy' design, meaning that half the participants got active injectable cabotegravir and inactive placebo pills; the other half got inactive placebo injections and active tenofovir/emtricitabine pills.
Read More
